{"id":926723,"date":"2026-01-13T08:53:40","date_gmt":"2026-01-13T13:53:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/"},"modified":"2026-01-13T08:53:40","modified_gmt":"2026-01-13T13:53:40","slug":"euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/","title":{"rendered":"EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform"},"content":{"rendered":"<div class=\"mw_release\">\n<p>\n        <strong>SINGAPORE, Jan.  13, 2026  (GLOBE NEWSWIRE) &#8212; <\/strong>\u00a0EUDA Health Holdings Limited (NASDAQ: EUDA) (\u201cEUDA\u201d or the \u201cCompany\u201d), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that its wholly owned subsidiary, EUDA Health Pte. Ltd. (\u201cEUDA Health\u201d), has entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd. (\u201cShenzhen Inno\u201d), a developer of autologous cellular therapeutics and customised medicines for a wide range of diseases in China.<\/p>\n<p>\n        <b>Strategic Investment and Facility Expansion Plan<\/b>\n      <\/p>\n<p>Under the terms of the agreement, EUDA expects to invest up to RMB 6 million in two tranches, consisting of an initial tranche of RMB 1 million and a second tranche of RMB 5 million, subject to the completion of due diligence, regulatory approvals, and execution of definitive agreements.<\/p>\n<p>Shenzhen Inno will deploy the capital to upgrade its cGMP facility in Shenzhen to create a state-of-the-art production and innovation center for stem cell treatments. The facility is expected to serve as a core technology and operating hub for EUDA\u2019s China strategy, anchoring EUDA\u2019s regenerative medicine capabilities, supporting international collaborations, and providing a replicable platform for expansion into additional cities and markets.<\/p>\n<p>The investment is structured as a convertible loan note that provides the optionality for EUDA to convert into equity interest in Shenzhen Inno, with the resulting ownership percentage to be determined at the time of conversion based on valuation and definitive documentation. The convertible loan note is expected to carry an interest rate of 6% per annum, payable semi-annually, and may be redeemed with accrued interest if not converted, subject to the final terms.<\/p>\n<p>Shenzhen Inno operates a stem cell technology and therapy platform focused on advanced human cell processing, quality controlled cell culture, precision biological workflows and regulated laboratory operations supporting natural killer cell, gamma delta T cell, cytokine induced killer cell, mesenchymal stem cell, induced pluripotent stem cell and organoid based programs. The platform integrates biological processing infrastructure, quality and compliance systems, and scalable operating processes designed to support both clinical and research applications.<\/p>\n<p>\n        <b>Shenzhen Inno \u2013 Strong Institutional Backing<\/b>\n      <\/p>\n<p>In August 2017, HSG Capital Group (\u201cHSG\u201d), \u00a0formerly known as Sequoia Capital China, a leading international venture capital and private equity firm, strategically invested approximately US$8 million in Shenzhen Inno. The capital provided early institutional validation of its scientific platform, regulatory foundation, long term commercial potential, and supported the development of its laboratory infrastructure, quality systems and core technical team.<\/p>\n<p>\n        <b>Mr Alfred Lim, Chief Executive Officer of EUDA, commented:<\/b>\n      <\/p>\n<p>\u201cThis agreement reflects our disciplined approach to building long-term stem cell therapy platforms. By supporting the upgrade and expansion of a high-quality platform using a phased and flexible investment structure, we can validate execution, align our strategies, and create the foundation for deeper ownership and integration over time. This positions EUDA not only as a healthcare provider, but as a vertically integrated platform with technology, infrastructure and operational depth.\u201d<\/p>\n<p>\n        <b>About EUDA Health Holdings Limited<\/b>\n      <\/p>\n<p>EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p>This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words \u201cestimates,\u201d \u201cprojected,\u201d \u201cexpects,\u201d \u201cenvisions,\u201d \u201canticipates,\u201d \u201cforecasts,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cbelieves,\u201d \u201cseeks,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cfuture,\u201d \u201cpropose\u201d and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA\u2019s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n<p>Christensen Advisory<\/p>\n<p>Christian Arnell<\/p>\n<p>Phone: + 852 9040 0621<\/p>\n<p>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-nb1eBIyCRrubmyaCuZO5Qyr4oVoamOyf3YgAJwjQE4TQfrFkvyJzoOEE6ESWHloZ6jDGhfXFORfGSYgK9Tys8yN2vB1_BqVewNnXHP7_Sgh8e1YBNCeDofpz89Ms4J5knY1P9oGksCs64VLwrP5TA==\" rel=\"nofollow\" target=\"_blank\">christian.arnell@christensencomms.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDcyMyM3MzU4NTg2IzUwMDEyNDQzOQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YWMyYmUxYjMtNDRhMS00NWRjLWJiOGMtNGQwNDFiYWZlNmYxLTUwMDEyNDQzOS0yMDI2LTAxLTEzLWVu\/tiny\/EUDA-Health-Holdings-Ltd.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) &#8212; \u00a0EUDA Health Holdings Limited (NASDAQ: EUDA) (\u201cEUDA\u201d or the \u201cCompany\u201d), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that its wholly owned subsidiary, EUDA Health Pte. Ltd. (\u201cEUDA Health\u201d), has entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd. (\u201cShenzhen Inno\u201d), a developer of autologous cellular therapeutics and customised medicines for a wide range of diseases in China. Strategic Investment and Facility Expansion Plan Under the terms of the agreement, EUDA expects to invest up to RMB 6 million in two tranches, consisting of an initial tranche of RMB 1 million and a second tranche of RMB 5 million, subject to the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-926723","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) &#8212; \u00a0EUDA Health Holdings Limited (NASDAQ: EUDA) (\u201cEUDA\u201d or the \u201cCompany\u201d), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that its wholly owned subsidiary, EUDA Health Pte. Ltd. (\u201cEUDA Health\u201d), has entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd. (\u201cShenzhen Inno\u201d), a developer of autologous cellular therapeutics and customised medicines for a wide range of diseases in China. Strategic Investment and Facility Expansion Plan Under the terms of the agreement, EUDA expects to invest up to RMB 6 million in two tranches, consisting of an initial tranche of RMB 1 million and a second tranche of RMB 5 million, subject to the &hellip; Continue reading &quot;EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T13:53:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDcyMyM3MzU4NTg2IzUwMDEyNDQzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform\",\"datePublished\":\"2026-01-13T13:53:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\\\/\"},\"wordCount\":772,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNDcyMyM3MzU4NTg2IzUwMDEyNDQzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\\\/\",\"name\":\"EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNDcyMyM3MzU4NTg2IzUwMDEyNDQzOQ==\",\"datePublished\":\"2026-01-13T13:53:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNDcyMyM3MzU4NTg2IzUwMDEyNDQzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNDcyMyM3MzU4NTg2IzUwMDEyNDQzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/","og_locale":"en_US","og_type":"article","og_title":"EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform - Market Newsdesk","og_description":"SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) &#8212; \u00a0EUDA Health Holdings Limited (NASDAQ: EUDA) (\u201cEUDA\u201d or the \u201cCompany\u201d), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that its wholly owned subsidiary, EUDA Health Pte. Ltd. (\u201cEUDA Health\u201d), has entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd. (\u201cShenzhen Inno\u201d), a developer of autologous cellular therapeutics and customised medicines for a wide range of diseases in China. Strategic Investment and Facility Expansion Plan Under the terms of the agreement, EUDA expects to invest up to RMB 6 million in two tranches, consisting of an initial tranche of RMB 1 million and a second tranche of RMB 5 million, subject to the &hellip; Continue reading \"EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-13T13:53:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDcyMyM3MzU4NTg2IzUwMDEyNDQzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform","datePublished":"2026-01-13T13:53:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/"},"wordCount":772,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDcyMyM3MzU4NTg2IzUwMDEyNDQzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/","name":"EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDcyMyM3MzU4NTg2IzUwMDEyNDQzOQ==","datePublished":"2026-01-13T13:53:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDcyMyM3MzU4NTg2IzUwMDEyNDQzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDcyMyM3MzU4NTg2IzUwMDEyNDQzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/euda-enters-into-convertible-loan-agreement-with-shenzhen-inno-further-expanding-stem-cell-therapy-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/926723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=926723"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/926723\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=926723"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=926723"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=926723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}